{
    "root": "2eacec81-3528-a573-e063-6394a90a6da4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ivabradine",
    "value": "20250224",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "GLYCERYL MONOCAPRYLOCAPRATE",
            "code": "G7515SW10N"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYVINYL ALCOHOL GRAFT POLYETHYLENE GLYCOL COPOLYMER (3:1; 45000 MW)",
            "code": "23ZQ42JZZH"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "IVABRADINE HYDROCHLORIDE",
            "code": "TP19837BZK"
        }
    ],
    "indications": "Ivabradine is a hyperpolarization-activated cyclic nucleotide‑gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 )",
    "contraindications": "Adult patients Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 )",
    "warningsAndPrecautions": "Ivabradine tablets 5 mg are formulated as orange-colored, oval-shaped, film-coated tablets functionally scored on both edges, marked with “I5” on one face and bisected on the other face.  They are supplied as follows:\n                  \n                     Bottles of 60 tablets with child-resistant closure (NDC 69452-190-17)\n                     Bottles of 500 tablets (NDC 69452-190-30)\n                  \n                  Ivabradine tablets 7.5 mg are formulated as orange-colored, triangular-shaped, film-coated tablets debossed with “7.5” on one face and plain on the other face.  They are supplied as follows:\n                  \n                     Bottles of 60 tablets with child-resistant closure (NDC 69452-191-17)\n                     Bottles of 500 tablets (NDC 69452-191-30)\n                  \n                  \n                     \n                        Storage\n                     \n                  \n                  Store ivabradine tablets at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Ivabradine is contraindicated in patients with:\n                  \n                     Acute decompensated heart failure\n                     Clinically significant hypotension\n                     Sick sinus syndrome, sinoatrial block or 3\n  \n   rd degree AV block, unless a functioning demand pacemaker is present\n \n  \n                     Clinically significant bradycardia\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   \n                     \n                     Severe hepatic impairment\n  \n   [see Use in Specific Populations (\n   \n    8.6)]\n  \n   \n                     \n                     Pacemaker dependence (heart rate maintained exclusively by the pacemaker)\n  \n   [see Drug Interactions (\n   \n    7.3)]\n  \n   \n                     \n                     Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors\n  \n   [see Drug Interactions (\n   \n    7.1)]"
}